CTI BioPharma (NASDAQ:CTIC) : The most positive equity analysts on CTI BioPharma (NASDAQ:CTIC) expects the shares to touch $5, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $2.88 with an expected fluctuation of $3.01 from the mean.
Other Equity analysts have also commented on the company shares. Piper Jaffray downgrades its view on CTI BioPharma (NASDAQ:CTIC) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Overweight. Piper Jaffray lowers the current price target of $0.75 per share on CTI BioPharma . The rating by the firm was issued on February 10, 2016.
CTI BioPharma (NASDAQ:CTIC): stock turned positive on Thursday. Though the stock opened at $0.4148, the bulls momentum made the stock top out at $0.4164 level for the day. The stock recorded a low of $0.4 and closed the trading day at $0.4026, in the green by 2.94%. The total traded volume for the day was 2,288,374. The stock had closed at $0.3911 in the previous days trading.
The company shares have dropped -81.69% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $2.19 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $0.43 and the 200 Day Moving Average price is recorded at $0.71. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Bianco James A, director officer (President and CEO) of Cti Biopharma Corp, had unloaded 10,000 shares at an average price of $0.45 in a transaction dated on May 27, 2016. The total value of the transaction was worth $4,500.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.